BIIB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

2.21B

-9.88%

1.756

-48.97%

2.26B

-7.09%

3.535

+17.07%

2.37B

-10.36%

3.910

-28.52%

Estimates Revision

The market is revising Upward the revenue expectations for Biogen Inc. (BIIB) for FY2025, with the revenue forecasts being adjusted by 1.88% over the past three months. During the same period, the stock price has changed by 21.50%.

Revenue Estimates for FY2025

Revise Upward

+1.88%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-4.34%

In Past 3 Month

Stock Price

Go Up

+21.50%

In Past 3 Month

22 Analyst Rating

Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 184.00 USD with a low forecast of 149.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

10 Hold

0 Sell

Moderate Buy

Current: 174.137

Low

149.00

Averages

184.00

High

250.00

Current: 174.137

Low

149.00

Averages

184.00

High

250.00

Morgan Stanley

Terence Flynn

Equal Weight

maintain

$149 -> $156

2025-12-12

New

Reason

Morgan Stanley

Terence Flynn

Price Target

$149 -> $156

2025-12-12

New

maintain

Equal Weight

Reason

Morgan Stanley analyst Terence Flynn raised the firm's price target on Biogen to $156 from $149 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.

HSBC

Hold -> Reduce

downgrade

$144 -> $143

2025-12-10

New

Reason

HSBC

Price Target

$144 -> $143

2025-12-10

New

downgrade

Hold -> Reduce

Reason

HSBC downgraded Biogen to Reduce from Hold with a price target of $143, down from $144. The company's "ailing" multiple sclerosis franchise is outweighing its growth elsewhere, the analyst tells investors in a research note. The firm expects margin pressure from lower royalties and says Biogen's 50% share re-rating is overdone. The company has limited near-term earnings improvement potential and risk to its long-term earnings power, contends HSBC.

Piper Sandler

Neutral

maintain

$118 -> $157

2025-11-21

Reason

Piper Sandler

Price Target

$118 -> $157

2025-11-21

maintain

Neutral

Reason

Piper Sandler raised the firm's price target on Biogen to $157 from $118 and keeps a Neutral rating on the shares. The firm notes that Biogen shares have certainly participated in the broader rally of the biopharma space in recent months, with the stock up about 35% since the beginning of Q3 2025.

Stifel

Hold -> Buy

upgrade

$144 -> $202

2025-11-06

Reason

Stifel

Price Target

$144 -> $202

2025-11-06

upgrade

Hold -> Buy

Reason

Stifel upgraded Biogen to Buy from Hold with a price target of $202, up from $144, following the Q3 report. The firm believes the stock's risk/reward is shifting favorably with clinical catalysts ahead. The upgrade is not a call on the base business, as Biogen's Q3 results were mixed and Q4 "will be just okay," the analyst tells investors in a research note. However, Stifel believes Biogen shares can trade higher in the next 12 months due to a "narrative shift" in Alzheimer's. This will be supported by potential success of Eli Lily's TRAILBLAZER-ALZ 3 trial, which could fundamentally change the way doctors and investors think about amyloid beta antibodies, the analyst tells investors in a research note. Biogen offers "unique optionality even if clinical catalysts still have risks," contends the firm.

Bernstein

Market Perform

maintain

$155 -> $157

2025-11-03

Reason

Bernstein

Price Target

$155 -> $157

2025-11-03

maintain

Market Perform

Reason

Bernstein raised the firm's price target on Biogen to $157 from $155 and keeps a Market Perform rating on the shares following quarterly results. The performance of multiple sclerosis Franchise and to a lesser extent Anti-CD20 drove the revenue beat, outpacing consensus by 14% and 10%, respectively, the firm notes. Leqembi's miss took away the shine from this beat, and while this can be partly explained by channel dynamics, the broader competitive environment looks increasingly challenging, Bernstein adds.

Baird

Outperform

NULL

downgrade

$255 -> $250

2025-10-31

Reason

Baird

Price Target

$255 -> $250

2025-10-31

downgrade

Outperform

NULL

Reason

Baird lowered the firm's price target on Biogen to $250 from $255 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results where its beat was driven by MS as its launch products are showing slow growth.

Valuation Metrics

The current forward P/E ratio for Biogen Inc (BIIB.O) is 13.50, compared to its 5-year average forward P/E of 14.12. For a more detailed relative valuation and DCF analysis to assess Biogen Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

14.12

Current PE

13.50

Overvalued PE

17.53

Undervalued PE

10.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.32

Current EV/EBITDA

10.29

Overvalued EV/EBITDA

12.71

Undervalued EV/EBITDA

7.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.42

Current PS

2.77

Overvalued PS

4.22

Undervalued PS

2.61

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BIIB News & Events

Events Timeline

No data

News

4.5

12-13MarketWatch

Walmart Missed Out on Nasdaq-100 Inclusion, While These 6 Stocks Secured Their Place

8.5

12-13Newsfilter

Nasdaq Adds Six Companies to Nasdaq-100 Index Effective December 22, 2025

4.5

12-13NASDAQ.COM

Nasdaq-100 Index to Add Six New Companies and Remove Six Others Starting December 22

People Also Watch

Frequently Asked Questions

What is Biogen Inc (BIIB) stock price today?

The current price of BIIB is 174.1375 USD — it has increased 0.02 % in the last trading day.

What is Biogen Inc (BIIB)'s business?

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

What is the price predicton of BIIB Stock?

What is Biogen Inc (BIIB)'s revenue for the last quarter?

Biogen Inc revenue for the last quarter amounts to 2.53B USD, increased 2.79 % YoY.

What is Biogen Inc (BIIB)'s earnings per share (EPS) for the last quarter?

Biogen Inc. EPS for the last quarter amounts to 3.17 USD, increased 19.17 % YoY.

What changes have occurred in the market's expectations for Biogen Inc (BIIB)'s fundamentals?

How many employees does Biogen Inc (BIIB). have?

Biogen Inc (BIIB) has 7605 emplpoyees as of December 15 2025.

What is Biogen Inc (BIIB) market cap?

Today BIIB has the market capitalization of 25.54B USD.